Exosomal UCA1 can enhance gefitinib resistance in NSCLC by increasing FOSL2 expression via sponging miR-143, which contributes to the limited therapeutic efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) 112. This evidence concerns the gene FOSL2 and non-small cell lung carcinoma.